Identification

Name
SRT501
Accession Number
DB05073
Type
Small Molecule
Groups
Investigational
Description

SRT501 is a small molecule develped for the treatment of metabolic diseases like diabetes and obesity. It is the first small molecule, designed to target SIRT1, to enter the clinic.

Synonyms
Not Available
Categories
UNII
Not Available
CAS number
Not Available
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in diabetes mellitus type 2 and neurologic disorders.

Structured Indications
Not Available
Pharmacodynamics

SRT501 is the first small molecule, designed to target SIRT1, to enter the clinic. SIRT1 is the founding member of the human sirtuin family of enzymes. Specifically, SRT501 acts by increasing mitochondrial activity and is thus therapeutically targeted to address metabolic diseases like diabetes and obesity.

Mechanism of action
TargetActionsOrganism
UNAD-dependent protein deacetylase sirtuin-1Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when SRT501 is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when SRT501 is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when SRT501 is combined with 5-androstenedione.Experimental, Illicit
AbciximabSRT501 may increase the anticoagulant activities of Abciximab.Approved
AcebutololSRT501 may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when SRT501 is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when SRT501 is combined with Acemetacin.Approved
AcenocoumarolSRT501 may increase the anticoagulant activities of Acenocoumarol.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of SRT501.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of SRT501.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when SRT501 is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinSRT501 may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with SRT501.Approved
AlclofenacThe risk or severity of adverse effects can be increased when SRT501 is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when SRT501 is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when SRT501 is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when SRT501 is combined with Alendronic acid.Approved
AliskirenSRT501 may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when SRT501 is combined with Alminoprofen.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when SRT501 is combined with Aloxiprin.Experimental
AlprenololSRT501 may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with SRT501.Approved, Investigational
AlteplaseSRT501 may increase the anticoagulant activities of Alteplase.Approved
ALX-0081SRT501 may increase the anticoagulant activities of ALX-0081.Investigational
AmcinonideThe risk or severity of adverse effects can be increased when SRT501 is combined with Amcinonide.Approved
AmikacinSRT501 may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideSRT501 may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when SRT501 is combined with Aminosalicylic Acid.Approved
AmrubicinSRT501 may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AnagrelideSRT501 may increase the anticoagulant activities of Anagrelide.Approved
AncrodSRT501 may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when SRT501 is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when SRT501 is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when SRT501 is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when SRT501 is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when SRT501 is combined with Anisodamine.Investigational
AnistreplaseSRT501 may increase the anticoagulant activities of Anistreplase.Approved
annamycinSRT501 may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with SRT501.Approved
Antithrombin III humanSRT501 may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when SRT501 is combined with Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when SRT501 is combined with Apocynin.Investigational
ApramycinSRT501 may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when SRT501 is combined with Apremilast.Approved, Investigational
ArbekacinSRT501 may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinSRT501 may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanSRT501 may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololSRT501 may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
AstaxanthinSRT501 may increase the anticoagulant activities of Astaxanthin.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when SRT501 is combined with Atamestane.Investigational
AtenololSRT501 may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when SRT501 is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with SRT501.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with SRT501.Approved
BalsalazideSRT501 may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BatroxobinSRT501 may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminSRT501 may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when SRT501 is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololSRT501 may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinSRT501 may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BemiparinSRT501 may increase the anticoagulant activities of Bemiparin.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with SRT501.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when SRT501 is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with SRT501.Approved
BenorilateThe risk or severity of adverse effects can be increased when SRT501 is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with SRT501.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when SRT501 is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with SRT501.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when SRT501 is combined with Betamethasone.Approved, Vet Approved
BetaxololSRT501 may decrease the antihypertensive activities of Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of SRT501.Approved, Investigational
BevantololSRT501 may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when SRT501 is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with SRT501.Approved, Investigational
BisoprololSRT501 may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinSRT501 may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololSRT501 may decrease the antihypertensive activities of Bopindolol.Approved
BrinaseSRT501 may increase the anticoagulant activities of Brinase.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with SRT501.Approved
BucillamineThe risk or severity of adverse effects can be increased when SRT501 is combined with Bucillamine.Investigational
BucindololSRT501 may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when SRT501 is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when SRT501 is combined with Bufexamac.Experimental
BuflomedilSRT501 may increase the antiplatelet activities of Buflomedil.Experimental
BufuralolSRT501 may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when SRT501 is combined with Bumadizone.Experimental
BumetanideSRT501 may decrease the diuretic activities of Bumetanide.Approved
BupranololSRT501 may decrease the antihypertensive activities of Bupranolol.Approved
ButylphthalideSRT501 may increase the antiplatelet activities of Butylphthalide.Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with SRT501.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with SRT501.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with SRT501.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with SRT501.Experimental
CangrelorSRT501 may increase the anticoagulant activities of Cangrelor.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with SRT501.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when SRT501 is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with SRT501.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with SRT501.Approved, Vet Approved, Withdrawn
CarteololSRT501 may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolSRT501 may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with SRT501.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with SRT501.Approved, Investigational
CeliprololSRT501 may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinSRT501 may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with SRT501.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with SRT501.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with SRT501.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of SRT501 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with SRT501.Approved
CiclesonideThe risk or severity of adverse effects can be increased when SRT501 is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with SRT501.Approved
CilostazolSRT501 may increase the anticoagulant activities of Cilostazol.Approved
CinoxacinSRT501 may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidSRT501 may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when SRT501 is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when SRT501 is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when SRT501 is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when SRT501 is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when SRT501 is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when SRT501 is combined with Clonixin.Approved
ClopidogrelSRT501 may increase the anticoagulant activities of Clopidogrel.Approved, Nutraceutical
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with SRT501.Vet Approved
CloranololSRT501 may decrease the antihypertensive activities of Cloranolol.Experimental
CloricromenSRT501 may increase the anticoagulant activities of Cloricromen.Experimental
ClorindioneSRT501 may increase the anticoagulant activities of Clorindione.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of SRT501 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of SRT501 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when SRT501 is combined with Collagenase clostridium histolyticum.Approved, Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when SRT501 is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when SRT501 is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when SRT501 is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when SRT501 is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with SRT501.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of SRT501.Approved, Investigational
CyclosporineSRT501 may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of SRT501.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when SRT501 is combined with D-Limonene.Investigational
Dabigatran etexilateSRT501 may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinSRT501 may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidSRT501 may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanSRT501 may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of SRT501.Approved, Investigational
DaunorubicinSRT501 may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when SRT501 is combined with Deferasirox.Approved, Investigational
DefibrotideSRT501 may increase the anticoagulant activities of Defibrotide.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when SRT501 is combined with Deflazacort.Approved
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with SRT501.Experimental
Deoxycholic AcidThe risk or severity of adverse effects can be increased when SRT501 is combined with Deoxycholic Acid.Approved
dersalazineThe risk or severity of adverse effects can be increased when SRT501 is combined with dersalazine.Investigational
DesirudinSRT501 may increase the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of SRT501.Approved
DesmopressinThe risk or severity of adverse effects can be increased when SRT501 is combined with Desmopressin.Approved
DesmoteplaseSRT501 may increase the anticoagulant activities of Desmoteplase.Investigational
DesonideThe risk or severity of adverse effects can be increased when SRT501 is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when SRT501 is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when SRT501 is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when SRT501 is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when SRT501 is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when SRT501 is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with SRT501.Approved, Investigational
DextranSRT501 may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40SRT501 may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70SRT501 may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75SRT501 may increase the anticoagulant activities of Dextran 75.Approved
DibekacinSRT501 may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with SRT501.Approved, Vet Approved
DicoumarolSRT501 may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when SRT501 is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when SRT501 is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when SRT501 is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when SRT501 is combined with Difluocortolone.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when SRT501 is combined with Difluprednate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of SRT501.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with SRT501.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of SRT501.Approved
DihydrostreptomycinSRT501 may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with SRT501.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with SRT501.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with SRT501.Approved
DiphenadioneSRT501 may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleSRT501 may increase the anticoagulant activities of Dipyridamole.Approved
DitazoleSRT501 may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with SRT501.Approved, Investigational
DoxorubicinSRT501 may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneSRT501 may increase the hyperkalemic activities of Drospirenone.Approved
Drotrecogin alfaSRT501 may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when SRT501 is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when SRT501 is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when SRT501 is combined with E-6201.Investigational
Edetic AcidSRT501 may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanSRT501 may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with SRT501.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with SRT501.Approved
EnoxacinSRT501 may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinSRT501 may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with SRT501.Experimental
EpanololSRT501 may decrease the antihypertensive activities of Epanolol.Experimental
EpinastineEpinastine may increase the antiplatelet activities of SRT501.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when SRT501 is combined with Epirizole.Approved
EpirubicinSRT501 may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneSRT501 may decrease the antihypertensive activities of Eplerenone.Approved
EplivanserinSRT501 may increase the anticoagulant activities of Eplivanserin.Investigational
eplivanserineSRT501 may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolEpoprostenol may increase the antiplatelet activities of SRT501.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with SRT501.Approved
EptifibatideSRT501 may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when SRT501 is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when SRT501 is combined with Equilin.Approved
EsmololSRT501 may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when SRT501 is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when SRT501 is combined with Estrone sulfate.Approved
Etacrynic acidSRT501 may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with SRT501.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when SRT501 is combined with Ethenzamide.Experimental
Ethyl biscoumacetateSRT501 may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when SRT501 is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with SRT501.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when SRT501 is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with SRT501.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when SRT501 is combined with Evening primrose oil.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when SRT501 is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when SRT501 is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when SRT501 is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with SRT501.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with SRT501.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when SRT501 is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when SRT501 is combined with Feprazone.Experimental
Ferulic acidSRT501 may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinSRT501 may increase the anticoagulant activities of Fibrinolysin.Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with SRT501.Approved, Investigational
FleroxacinSRT501 may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with SRT501.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when SRT501 is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when SRT501 is combined with Fludrocortisone.Approved
FluindioneSRT501 may increase the anticoagulant activities of Fluindione.Investigational
FlumequineSRT501 may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when SRT501 is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when SRT501 is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when SRT501 is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when SRT501 is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when SRT501 is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when SRT501 is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when SRT501 is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when SRT501 is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when SRT501 is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when SRT501 is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with SRT501.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when SRT501 is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with SRT501.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when SRT501 is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when SRT501 is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with SRT501.Approved, Nutraceutical, Vet Approved
FondaparinuxSRT501 may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumSRT501 may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with SRT501.Experimental
FormestaneThe risk or severity of adverse effects can be increased when SRT501 is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with SRT501.Approved
FramycetinSRT501 may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideSRT501 may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateSRT501 may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinSRT501 may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinSRT501 may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with SRT501.Approved, Withdrawn
GemifloxacinSRT501 may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinSRT501 may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinSRT501 may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ASRT501 may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GitoformateGitoformate may decrease the cardiotoxic activities of SRT501.Experimental
GlucosamineGlucosamine may increase the antiplatelet activities of SRT501.Approved
GPX-150SRT501 may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinSRT501 may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when SRT501 is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when SRT501 is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when SRT501 is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when SRT501 is combined with HE3286.Investigational
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when SRT501 is combined with Hemoglobin crosfumaril.Experimental
HeparinSRT501 may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineSRT501 may increase the anticoagulant activities of Higenamine.Investigational
HydralazineSRT501 may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with SRT501.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when SRT501 is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with SRT501.Approved, Investigational
HydroxytyrosolSRT501 may increase the antiplatelet activities of Hydroxytyrosol.Investigational
Hygromycin BSRT501 may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when SRT501 is combined with Ibandronate.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when SRT501 is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with SRT501.Approved
IbudilastSRT501 may increase the antiplatelet activities of Ibudilast.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with SRT501.Approved
IbuproxamThe risk or severity of adverse effects can be increased when SRT501 is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when SRT501 is combined with Icatibant.Approved
Icosapent ethylSRT501 may increase the antiplatelet activities of Icosapent ethyl.Approved, Nutraceutical
IdarubicinSRT501 may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxSRT501 may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilSRT501 may increase the antiplatelet activities of Ifenprodil.Approved, Investigational, Withdrawn
IfetrobanSRT501 may increase the antiplatelet activities of Ifetroban.Investigational
IloprostIloprost may increase the antiplatelet activities of SRT501.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with SRT501.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when SRT501 is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with SRT501.Approved
IndenololSRT501 may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenSRT501 may increase the anticoagulant activities of Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with SRT501.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when SRT501 is combined with Indoprofen.Withdrawn
INNO-206SRT501 may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with SRT501.Approved, Investigational
IsepamicinSRT501 may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when SRT501 is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when SRT501 is combined with Istaroxime.Investigational
KanamycinSRT501 may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when SRT501 is combined with Kebuzone.Experimental
KetanserinSRT501 may increase the antiplatelet activities of Ketanserin.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with SRT501.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with SRT501.Approved
LabetalolSRT501 may decrease the antihypertensive activities of Labetalol.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of SRT501.Experimental
LandiololSRT501 may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with SRT501.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with SRT501.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with SRT501.Approved, Investigational
LepirudinSRT501 may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanSRT501 may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololSRT501 may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinSRT501 may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostLimaprost may increase the antiplatelet activities of SRT501.Approved, Investigational
LinsidomineSRT501 may increase the antiplatelet activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with SRT501.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when SRT501 is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with SRT501.Approved
LonazolacThe risk or severity of adverse effects can be increased when SRT501 is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when SRT501 is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with SRT501.Approved
LoteprednolThe risk or severity of adverse effects can be increased when SRT501 is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when SRT501 is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with SRT501.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with SRT501.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with SRT501.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with SRT501.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with SRT501.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when SRT501 is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with SRT501.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when SRT501 is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with SRT501.Approved
MelagatranSRT501 may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when SRT501 is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with SRT501.Approved, Vet Approved
MepindololSRT501 may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when SRT501 is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with SRT501.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with SRT501.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with SRT501.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when SRT501 is combined with Methyl salicylate.Approved, Vet Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when SRT501 is combined with Methylprednisolone.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of SRT501.Experimental
MetipranololSRT501 may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with SRT501.Approved
MetoprololSRT501 may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideSRT501 may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinSRT501 may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MilrinoneMilrinone may increase the antiplatelet activities of SRT501.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with SRT501.Approved
MizoribineThe risk or severity of adverse effects can be increased when SRT501 is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with SRT501.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when SRT501 is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when SRT501 is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with SRT501.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with SRT501.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with SRT501.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with SRT501.Approved
NadololSRT501 may decrease the antihypertensive activities of Nadolol.Approved
NadroparinSRT501 may increase the anticoagulant activities of Nadroparin.Approved
NafamostatSRT501 may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with SRT501.Approved
NaftopidilSRT501 may increase the antiplatelet activities of Naftopidil.Investigational
Nalidixic AcidSRT501 may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with SRT501.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when SRT501 is combined with NCX 1022.Investigational
NeamineSRT501 may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololSRT501 may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinSRT501 may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinSRT501 may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with SRT501.Approved
NetilmicinSRT501 may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when SRT501 is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with SRT501.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with SRT501.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when SRT501 is combined with Nitroaspirin.Investigational
NorfloxacinSRT501 may increase the neuroexcitatory activities of Norfloxacin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when SRT501 is combined with Obinutuzumab.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of SRT501.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when SRT501 is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with SRT501.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with SRT501.Approved
OlsalazineSRT501 may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when SRT501 is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with SRT501.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of SRT501.Approved, Nutraceutical
OrgoteinThe risk or severity of adverse effects can be increased when SRT501 is combined with Orgotein.Vet Approved
OtamixabanSRT501 may increase the anticoagulant activities of Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of SRT501.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with SRT501.Approved
Oxolinic acidSRT501 may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololSRT501 may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with SRT501.Approved, Withdrawn
OzagrelSRT501 may increase the anticoagulant activities of Ozagrel.Investigational
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with SRT501.Approved, Vet Approved
PamidronateThe risk or severity of adverse effects can be increased when SRT501 is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when SRT501 is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when SRT501 is combined with Parecoxib.Approved
ParnaparinSRT501 may increase the anticoagulant activities of Parnaparin.Approved, Investigational
ParomomycinSRT501 may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when SRT501 is combined with Parthenolide.Investigational
PazufloxacinSRT501 may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinSRT501 may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololSRT501 may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateSRT501 may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with SRT501.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of SRT501.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with SRT501.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of SRT501.Experimental
PhenindioneSRT501 may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonSRT501 may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with SRT501.Approved, Vet Approved
PicotamideSRT501 may increase the anticoagulant activities of Picotamide.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with SRT501.Approved, Investigational
PindololSRT501 may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidSRT501 may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinSRT501 may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideSRT501 may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with SRT501.Approved, Investigational
Piromidic acidSRT501 may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with SRT501.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when SRT501 is combined with Pirprofen.Experimental
Platelet Activating FactorSRT501 may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinSRT501 may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinSRT501 may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with SRT501.Approved
PractololSRT501 may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with SRT501.Approved
PranoprofenThe risk or severity of adverse effects can be increased when SRT501 is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when SRT501 is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when SRT501 is combined with Prasterone sulfate.Investigational
PrasugrelSRT501 may increase the anticoagulant activities of Prasugrel.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when SRT501 is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when SRT501 is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when SRT501 is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when SRT501 is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe serum concentration of SRT501 can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when SRT501 is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when SRT501 is combined with Propacetamol.Approved, Investigational
PropranololSRT501 may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when SRT501 is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when SRT501 is combined with Proquazone.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of SRT501.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with SRT501.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with SRT501.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with SRT501.Vet Approved
Protein CSRT501 may increase the anticoagulant activities of Protein C.Approved
Protein S humanSRT501 may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeSRT501 may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinSRT501 may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when SRT501 is combined with PTC299.Investigational
PuromycinSRT501 may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with SRT501.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with SRT501.Approved
RamatrobanSRT501 may increase the antiplatelet activities of Ramatroban.Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with SRT501.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with SRT501.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with SRT501.Approved, Experimental, Investigational
ReteplaseSRT501 may increase the anticoagulant activities of Reteplase.Approved
ReviparinSRT501 may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinSRT501 may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RidogrelRidogrel may increase the antiplatelet activities of SRT501.Approved
RimexoloneThe risk or severity of adverse effects can be increased when SRT501 is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when SRT501 is combined with Risedronate.Approved, Investigational
RivaroxabanSRT501 may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with SRT501.Investigational, Withdrawn
RosiglitazoneSRT501 may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
RosoxacinSRT501 may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinSRT501 may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinSRT501 may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with SRT501.Approved
SalicylamideThe risk or severity of adverse effects can be increased when SRT501 is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when SRT501 is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with SRT501.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with SRT501.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with SRT501.Investigational
SarpogrelateSRT501 may increase the anticoagulant activities of Sarpogrelate.Investigational
SaruplaseSRT501 may increase the anticoagulant activities of Saruplase.Experimental
SelexipagSRT501 may increase the anticoagulant activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when SRT501 is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when SRT501 is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when SRT501 is combined with Serrapeptase.Investigational
SevofluraneSevoflurane may increase the antiplatelet activities of SRT501.Approved, Vet Approved
SisomicinSRT501 may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinSRT501 may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of SRT501.Approved
SotalolSRT501 may decrease the antihypertensive activities of Sotalol.Approved
SP1049CSRT501 may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinSRT501 may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinSRT501 may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with SRT501.Approved
SpironolactoneSRT501 may decrease the antihypertensive activities of Spironolactone.Approved
StreptokinaseSRT501 may increase the anticoagulant activities of Streptokinase.Approved, Investigational
StreptomycinSRT501 may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinSRT501 may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with SRT501.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with SRT501.Approved
SulodexideSRT501 may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with SRT501.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with SRT501.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when SRT501 is combined with Suxibuzone.Experimental
TacrolimusSRT501 may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with SRT501.Approved
TalinololSRT501 may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with SRT501.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when SRT501 is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with SRT501.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when SRT501 is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when SRT501 is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with SRT501.Approved, Investigational
TemafloxacinSRT501 may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with SRT501.Experimental, Investigational
TenecteplaseSRT501 may increase the anticoagulant activities of Tenecteplase.Approved
TenidapThe risk or severity of adverse effects can be increased when SRT501 is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when SRT501 is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with SRT501.Approved
TepoxalinThe risk or severity of adverse effects can be increased when SRT501 is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when SRT501 is combined with Teriflunomide.Approved
TertatololSRT501 may decrease the antihypertensive activities of Tertatolol.Experimental
TesmilifeneTesmilifene may increase the antiplatelet activities of SRT501.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with SRT501.Approved
TicagrelorSRT501 may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineSRT501 may increase the anticoagulant activities of Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when SRT501 is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololSRT501 may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when SRT501 is combined with Tinoridine.Investigational
TinzaparinSRT501 may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolSRT501 may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirTipranavir may increase the antiplatelet activities of SRT501.Approved, Investigational
TirofibanSRT501 may increase the anticoagulant activities of Tirofiban.Approved
TixocortolThe risk or severity of adverse effects can be increased when SRT501 is combined with Tixocortol.Approved
TobramycinSRT501 may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when SRT501 is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with SRT501.Approved
TorasemideSRT501 may decrease the diuretic activities of Torasemide.Approved
TositumomabThe risk or severity of adverse effects can be increased when SRT501 is combined with Tositumomab.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with SRT501.Approved
TranilastThe risk or severity of adverse effects can be increased when SRT501 is combined with Tranilast.Approved, Investigational
TrapidilSRT501 may increase the antiplatelet activities of Trapidil.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of SRT501.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with SRT501.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with SRT501.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when SRT501 is combined with Triamcinolone.Approved, Vet Approved
TriamtereneSRT501 may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when SRT501 is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with SRT501.Approved, Vet Approved
TriflusalSRT501 may increase the anticoagulant activities of Triflusal.Approved, Investigational
TriptolideThe risk or severity of adverse effects can be increased when SRT501 is combined with Triptolide.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when SRT501 is combined with Trolamine salicylate.Approved
TrovafloxacinSRT501 may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinSRT501 may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when SRT501 is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with SRT501.Approved
UrokinaseSRT501 may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with SRT501.Investigational, Withdrawn
ValrubicinSRT501 may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with SRT501.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with SRT501.Approved
Vitamin EVitamin E may increase the antiplatelet activities of SRT501.Approved, Nutraceutical, Vet Approved
VorapaxarSRT501 may increase the anticoagulant activities of Vorapaxar.Approved
WarfarinSRT501 may increase the anticoagulant activities of Warfarin.Approved
XimelagatranSRT501 may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when SRT501 is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with SRT501.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with SRT501.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when SRT501 is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with SRT501.Withdrawn
Zoptarelin doxorubicinSRT501 may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinSRT501 may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347909930

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceColorectal Cancers / Neoplasms, Colorectal1
2TerminatedTreatmentMultiple Myeloma (MM)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transcription factor binding
Specific Function
NAD-dependent protein deacetylase that links transcriptional regulation directly to intracellular energetics and participates in the coordination of several separated cellular functions such as cel...
Gene Name
SIRT1
Uniprot ID
Q96EB6
Uniprot Name
NAD-dependent protein deacetylase sirtuin-1
Molecular Weight
81680.06 Da

Drug created on October 21, 2007 16:23 / Updated on November 06, 2017 06:45